Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SPTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsSeaport Therapeutics completes IPO, Class A common stock capital structure (full multi-class details, if any, are in the charter exhibit / prospectus — not disclosed in this filing body) with 700M shares
Filed May 4, 2026 · Period ending May 4, 2026 · ~1 min read
Key Changes
-
high
Company authorized 700 million common shares split between 500 million voting and 200 million non-voting shares, creating a Class A common stock capital structure (full multi-class details, if any, are in the charter exhibit / prospectus — not disclosed in this filing body) that concentrates voting control with certain shareholders.
Item 5.03 verify on EDGAR → -
medium
Board authorized 10 million undesignated preferred shares that can be issued without shareholder approval, giving management flexibility for future capital raises or defensive measures.
Item 5.03 verify on EDGAR → -
low
Company eliminated all prior preferred stock series and filed amended certificate of incorporation with Delaware as part of standard IPO process.
Item 5.03 verify on EDGAR → -
low
Adopted new bylaws establishing formal procedures for stockholder meetings, advance notice requirements for proposals, and other public company governance standards.
Item 5.03 verify on EDGAR →
Summary
Seaport Therapeutics completed its initial public offering and made the standard corporate governance changes required for newly public companies. The most significant change is the Class A common stock capital structure (full multi-class details, if any, are in the charter exhibit / prospectus — not disclosed in this filing body): 500 million voting shares and 200 million non-voting shares.
This arrangement is common in biotech IPOs and allows founders or early investors to maintain voting control even as they sell economic stakes to public investors.
Retail investors should understand that the Class A common stock capital structure (full multi-class details, if any, are in the charter exhibit / prospectus — not disclosed in this filing body) means their votes will carry less weight than insiders' votes on major decisions like board elections or mergers. The company also authorized 10 million preferred shares that the board can issue at any time without asking shareholders, which could be used for future financing or as a takeover defense. Watch for the company's first quarterly earnings report and any disclosure about how voting versus non-voting shares are distributed among insiders. The prospectus filed around the IPO date will detail the exact ownership breakdown and voting power concentration.
Section-by-Section Diff
Event · Item 5.03 — Amendments to Articles of Incorporation or Bylaws
Seaport Therapeutics amended its certificate of incorporation and bylaws in connection with completing its initial public offering.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware
The company filed an amended and restated certificate of incorporation with Delaware in connection with completing its IPO. This is a standard corporate governance step when going public.
Event · Item 9.01 — Financial Statements and Exhibits
Seaport Therapeutics filed amended and restated certificate of incorporation and bylaws with no material business impact disclosed.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
Amended and Restated Certificate of Incorporation of Seaport Therapeutics, Inc.
The company filed an amended and restated certificate of incorporation. This is a routine corporate governance filing with no specific business changes disclosed in the 8-K body. The actual amendments would be detailed in the attached exhibit.
Added in current filing · verify on EDGAR →
Amended and Restated Bylaws of Seaport Therapeutics, Inc.
The company filed amended and restated bylaws. This is a routine corporate governance filing with no specific changes disclosed in the 8-K body. The actual amendments would be detailed in the attached exhibit.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify